At the 5-year follow-up, nivolumab plus ipilimumab continued to provide long-term, durable clinical benefit regardless of tumor PD-L1 expression versus chemotherapy, with no new safety concerns; the majority of 5-year survivors in the nivolumab plus ipilimumab arm did not initiate any subsequent systemic anticancer treatment for ≥ 3 years [11]. This evidence concerns the gene CD274 and neoplasm.